JP2023513106A5 - - Google Patents

Info

Publication number
JP2023513106A5
JP2023513106A5 JP2022547051A JP2022547051A JP2023513106A5 JP 2023513106 A5 JP2023513106 A5 JP 2023513106A5 JP 2022547051 A JP2022547051 A JP 2022547051A JP 2022547051 A JP2022547051 A JP 2022547051A JP 2023513106 A5 JP2023513106 A5 JP 2023513106A5
Authority
JP
Japan
Prior art keywords
use according
infection
group
compound
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547051A
Other languages
English (en)
Japanese (ja)
Other versions
JP7743080B2 (ja
JP2023513106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016854 external-priority patent/WO2021158941A1/en
Publication of JP2023513106A publication Critical patent/JP2023513106A/ja
Publication of JP2023513106A5 publication Critical patent/JP2023513106A5/ja
Application granted granted Critical
Publication of JP7743080B2 publication Critical patent/JP7743080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547051A 2020-02-07 2021-02-05 一酸化窒素放出抗菌化合物、製剤、およびそれらに関連する方法 Active JP7743080B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062971624P 2020-02-07 2020-02-07
US62/971,624 2020-02-07
PCT/US2021/016854 WO2021158941A1 (en) 2020-02-07 2021-02-05 Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto

Publications (3)

Publication Number Publication Date
JP2023513106A JP2023513106A (ja) 2023-03-30
JP2023513106A5 true JP2023513106A5 (https=) 2024-02-13
JP7743080B2 JP7743080B2 (ja) 2025-09-24

Family

ID=77199389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547051A Active JP7743080B2 (ja) 2020-02-07 2021-02-05 一酸化窒素放出抗菌化合物、製剤、およびそれらに関連する方法

Country Status (4)

Country Link
US (4) US20230108186A1 (https=)
EP (1) EP4093205A4 (https=)
JP (1) JP7743080B2 (https=)
WO (3) WO2021158941A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230108186A1 (en) * 2020-02-07 2023-04-06 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto
WO2023211932A1 (en) * 2022-04-28 2023-11-02 Know Bio, Llc Buffering agent-containing compositions and methods of using same
AU2023275534A1 (en) * 2022-05-23 2024-12-05 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics
CN119789870A (zh) * 2022-06-08 2025-04-08 诺欧生物有限责任公司 含有一氧化氮释放化合物的多组分药物组合物和试剂盒及其使用方法
AU2023384992B2 (en) * 2022-11-26 2025-07-17 Sterile State, Inc. Thiol-containing alcohols for generating nitric oxide and methods of forming the same
EP4676492A2 (en) * 2023-03-07 2026-01-14 KNOW Bio, LLC High purity nitric oxide releasing compounds and methods of preparing same
US20250339449A1 (en) * 2024-05-02 2025-11-06 Know Bio, Llc Inhalation formulations containing nitric oxide releasing compounds and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6203822B1 (en) * 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
BR9811473A (pt) * 1997-07-11 2001-12-26 Univ Johns Hopkins Med Infecção por rinovìrus inibida por óxido nìtrico
AU1770299A (en) * 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
EP1858525A2 (en) * 2005-02-16 2007-11-28 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (en) * 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
AU2006309212B2 (en) * 2005-10-31 2011-09-15 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
US8236341B2 (en) * 2009-04-02 2012-08-07 Medtronic Vascular, Inc. Poly(tetrafluoroethylene) polymer with nitric oxide donating surface
EP3166593B1 (en) * 2014-07-11 2020-05-20 Novan, Inc. Topical antiviral compositions and methods of using the same
US11072668B2 (en) * 2017-01-03 2021-07-27 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2019173539A1 (en) * 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US20230108186A1 (en) * 2020-02-07 2023-04-06 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto

Similar Documents

Publication Publication Date Title
JP2023513106A5 (https=)
JP2021533193A5 (https=)
Kanagalingam et al. Practical use of povidone‐iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections
US10792289B2 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
JP2021525526A5 (https=)
HRP20120262T1 (hr) Farmaceutske formulacije i postupci za liječenje infekcija dišnih puteva
JP2017510580A5 (https=)
EP2101787B1 (en) Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
JP2012502946A5 (https=)
EP2410986A2 (en) Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
RU2011136624A (ru) Способы уменьшения пролиферации и жизнеспособности микробных агентов
JP2020504778A5 (https=)
AU2015306137A1 (en) Iodophor composition with improved stability in the presence of organic material
US10471083B2 (en) Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
IL278571B2 (en) Antibacterial compounds
US20250281512A1 (en) Buffering agent-containing compositions and methods of using same
JP2013502416A (ja) 慢性閉塞性肺疾患治療用のエアロゾル化された抗生物の使用
CN119789870A (zh) 含有一氧化氮释放化合物的多组分药物组合物和试剂盒及其使用方法
Ibadov et al. Risk factors for the development and severe course of ventilator-associated tracheobronchitis in patients with prolonged mechanical ventilation
US20250134831A1 (en) Nasal Spray Compositions to Suppress Virus and Bacterial Pathogens and Methods of Use
Gilani et al. Antibacterial and antiadherent properties of silver dioxide-coated brackets
Karki et al. Is it worth adding systemic antibiotics to inhalational tobramycin therapy to treat pseudomonas infections in cystic fibrosis?
EP4338732A1 (en) Lefamulin and its derivatives for use in the treatment of tularemia
AU2015275224C1 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
US20150057242A1 (en) Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis